Glucose Control and Continuous Glucose Monitoring Metrics During 12 Months of Treatment with Tirzepatide in Overweight or Obese Patients with Type 1 Diabetes.

We conclude that adjunctive tirzepatide treatment in OW/OB adults with T1D was associated with sustained improvements in CGM metrics over 12 months, without increased hypoglycemia risk in this real-world study. Proper long-term randomized control trials are needed to confirm our findings.